Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously (days 1, 8, 15), every 4 weeks in patients with previously tr...

Full description

Bibliographic Details
Main Authors: Maria Angeles Gil-Delgado, Olivier Lucidarme, Jean Baptiste Bachet, Naima Mahi, David Khayat
Format: Article
Language:English
Published: Karger Publishers 2018-08-01
Series:Case Reports in Gastroenterology
Subjects:
Survival
Gastric cancer
Ramucirumab
Online Access:https://www.karger.com/Article/FullText/490906
id doaj-744f668e7bb049bc8567a77ab58b1f58
record_format Article
spelling doaj-744f668e7bb049bc8567a77ab58b1f582020-11-24T23:31:19ZengKarger PublishersCase Reports in Gastroenterology1662-06312018-08-0112253253910.1159/000490906490906Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: RamucirumabMaria Angeles Gil-DelgadoOlivier LucidarmeJean Baptiste BachetNaima MahiDavid KhayatWe report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016.https://www.karger.com/Article/FullText/490906SurvivalGastric cancerRamucirumab
collection DOAJ
language English
format Article
sources DOAJ
author Maria Angeles Gil-Delgado
Olivier Lucidarme
Jean Baptiste Bachet
Naima Mahi
David Khayat
spellingShingle Maria Angeles Gil-Delgado
Olivier Lucidarme
Jean Baptiste Bachet
Naima Mahi
David Khayat
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Case Reports in Gastroenterology
Survival
Gastric cancer
Ramucirumab
author_facet Maria Angeles Gil-Delgado
Olivier Lucidarme
Jean Baptiste Bachet
Naima Mahi
David Khayat
author_sort Maria Angeles Gil-Delgado
title Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_short Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_full Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_fullStr Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_full_unstemmed Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_sort long-term survival in gastroesophageal junction adenocarcinoma: ramucirumab
publisher Karger Publishers
series Case Reports in Gastroenterology
issn 1662-0631
publishDate 2018-08-01
description We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016.
topic Survival
Gastric cancer
Ramucirumab
url https://www.karger.com/Article/FullText/490906
work_keys_str_mv AT mariaangelesgildelgado longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT olivierlucidarme longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT jeanbaptistebachet longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT naimamahi longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT davidkhayat longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
_version_ 1725538451886964736

Similar Items